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Abstract
Background: Peroxidation of lipid (LPO) membrane and cholesterol metabolism have been involved in the
physiopathology of many diseases of aging brain. Therefore, this prospective animal study was carried firstly to find
out the correlation between LPO in posterior brain and plasmatic cholesterol along with lipoprotein levels after
chronic intoxication by aluminium chloride (AlCl3). Chronic aluminum-induced neurotoxicity has been in fact
related to enhanced brain lipid peroxidation together with hypercholesterolemia and hypertriglyceridemia, despite
its controversial etiological role in neurodegenerative diseases. Secondly an evaluation of the effectiveness of
fenugreek seeds in alleviating the engendered toxicity through these biochemical parameters was made.
Results: Oral administration of AlCl3 to rats during 5 months (500 mg/kg bw i.g for one month then 1600 ppm via
the drinking water) enhanced the levels of LPO in posterior brain, liver and plasma together with lactate
dehydrogenase (LDH) activities, total cholesterol (TC), triglycerides (TG) and LDL-C (Low Density Lipoproteins) levels.
All these parameters were decreased following fenugreek seeds supplementation either as fenugreek seed powder
(FSP) or fenugreek seed extract (FSE). A notable significant correlation was observed between LPObrain and LDL-C
on one hand and LDHliver on the other hand. This latter was found to correlate positively with TC, TG and LDL-C.
Furthermore, high significant correlations were observed between LDHbrain and TC, TG, LDL-C, LPObrain as well as
LDHliver.
Conclusion: Aluminium-induced LPO in brain could arise from alteration of lipid metabolism particularly altered
lipoprotein metabolism rather than a direct effect of cholesterol oxidation. Fenugreek seeds could play an anti-
peroxidative role in brain which may be attributed in part to its modulatory effect on plasmatic lipid metabolism.
Background
A close relationship between lipid peroxidation and
hypercholesterolemia and/or hyperlipidemia has been
evidenced in plasma, liver and aorta through many stu-
dies in animals and humans [1]. These factors contri-
bute to the process of several pathologies namely
atherosclerosis, but also seem implicated in the physio-
pathology of neurodegenerative diseases particularly
Alzheimer’s disease (AD) [2]. Indeed, lipid peroxidation
is considered as the most prominent form of oxidative
damage in neurodegenerative lesions due to the brain’s
relative enrichment in polyunsaturated fatty acids [3].
On the other hand, an increasing number of reviews
implicating cholesterol metabolism in the development
of AD have been published [4] which suggest cholesterol
as a target for treatment. However, although it is
admitted that an animal model able to reproduce all the
cognitive, behavioural, biochemical, and histopathologi-
cal abnormalities observed in AD patients does not exist
[5], a partial reproduction of some AD hallmarks, using
Al salts, have been achieved [6].
In this study, we aimed firstly to evaluate the relation-
ship between plasmatic cholesterol metabolism and lipid
peroxidation in posterior brain (parieto-temporal and
occipital regions), previously found to be preferentially
affected by AD [7], using Al, a potential etiological factor
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neurotoxicity has been in fact related to enhanced brain
lipid peroxidation [9] together with hypercholesterolemia
and hypertriglyceridemia [10].
Moreover, in the search for a new drug which may
offer neuroprotection by controling both hypercholester-
olemia and lipid peroxidation, we have tested fenugreek
seeds. Fenugreek (Trigonella foenum-graecum), a legume
cultivated predominantly in Asia, the Mediterranean and
North African regions for t h ee d i b l ea n dm e d i c i n a l
values of its seeds, has been reported to have antioxida-
tive and hypocholesterolemic properties [11]. Trigonella
is also known for its multiple pharmacological effects
including its antidiabetic, antineoplastic, anti-inflamma-
tory, antiulcerogenic, antipyretic, antitumor and immu-
nomodulatory effects [12]. The active components of
fenugreek seeds behind their most common properties
(i.e hypoglycemic, hypocholesterolemic, hypotriglyceri-
demic and antiperoxidative) have been described as
polyphenolic flavonoids [13], steroid saponins [14], poly-
saccharides mainly galactomannans [15] and 4-hydroxyi-
soleucine [16]. Nevertheless, the neuroprotective effect
of fenugreek seeds was mainly restricted to studies on
diabetes [17-19] except for a single in vitro study which
have demonstrated the acetylcholinesterase enzyme inhi-
bitory potential of standardized extract of fenugreek
seeds [12]. Thereby, the role of fenugreek seeds in neu-
rodegenerative diseases and especially against alumi-
num-induced changes has not so far been considered.
Results
Lipid profile and glucose levels in blood
Plasmatic levels of total cholesterol (+42.3%), LDL-C
(+63.52%), triglycerides (+81.81%), and glucose
(+97.85%) were found to be significantly increased in
Al-treated rats (Table 1), as compared to controls. No
significant changes were observed in rats consuming
fenugreek seeds and treated (AlCl3+FSP, AlCl3+FSE) or
not (FSP, FSE) with AlCl3.
HDL-C level was unchanged in Al-treated groups
(AlCl3, AlCl3+FSP and AlCl3+FSE), but significantly
increased when fenugreek seeds were administrated
alone either as FSP (+24.4%) or FSE (+10.2%).
Estimation of lipid peroxidation levels (TBARS)
After 5 months of exposure to AlCl3, a significant raise of
TBARS levels occurred increasingly in liver (+44.65%),
plasma (+47.56%) and brain (+78.42%) whereas no signifi-
cant changes were noted in (AlCl3+FSP) and (AlCl3+FSE)
groups (Table 2). In (FSP) and (FSE) treated rats, TBARS
levels were not significantly different from controls except
i nt h el i v e rw h e r ew en o t i c e da slight but significant
increase for both groups.
Lactate dehydrogenase (LDH) activity
As shown in Table 2 AlCl3 treatment induced an impor-
tant increase in plasmatic LDH release (+120.7%) and
relatively similar increase in liver and brain (+47.43%
and +36.39% respectively).
Correlation between measured parameters
Correlation analysis of TBARS and LDH in plasma, liver
and brain with plasmatic lipid and glucose profile are
illustrated in Table 3.
TBARS versus lipid profile
TBARS in brain, liver and plasma correlated positively
with TC, TG and LDL-C but the degree of correlation
is variable. Indeed, in posterior brain, TBARS was corre-
lated mostly with LDL-C (r = 0.767; p < 0.01) whereas
plasmatic TBARS correlated primarily with TG (r =
0.725; p < 0.01). In liver, correlation with all parameters
was low (0.280 < r < 0.394). Regarding HDL-C, no sig-
nificant correlation was recorded and it is expected
because AlCl3 has no effect on HDL-C (Table 1).
LDH versus lipid profile
LDH in brain, liver and plasma correlated positively
with TC, TG and LDL-C and negatively with HDL-C.
Distinctions existed yet between compartments. In fact,
Table 1 Lipid profile and blood glucose level in different experimental groups.
Parameter Experimental groups
Control AlCl3 AlCl3+FSP AlCl3+FSE FSP FSE
TC 1.56 ± 0.009 2.22a* ± 0.36 1.56
b* ± 0.01 1.61
b* ± 0.06 1.56 ± 0.08 1.55 ± 0.10
HDL-C 0.49 ± 0.02 0.44 ± 0.01 0.57
b*c ± 0.01 0.50
bc ± 0.004 0.61
a ± 0.03 0.54
a ± 0.01
LDL-C 0.85 ± 0.02 1.39
a* ± 0.03 0.89
b* ± 0.01 0.84
b* ± 0.04 0.83 ± 0.05 0.80 ± 0.05
TG 0.66 ± 0.02 1.20
a* ± 0.06 0.58
b* ± 0.02 0.74
b* ± 0.04 0.58 ± 0.14 0.68 ± 0.03
Glc 8.39 ± 0.03 16.6
a* ± 1.30 8.18
b* ± 0.08 7.85
b* ± 0.29 8.31 ± 0.02 8.18 ± 0.24
Values are expressed as means ± SD; n = 10 for each treatment group.
a Significant difference from the control group at p < 0.05.
b Significant difference from the AlCl3-intoxicated group at p < 0.05.
c Significant difference between AlCl3+FSP and AlCl3+FSE groups at p < 0.05.
* p < 0.001.
All parameters are expressed as mmol/l.
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TG and mainly LDL-C (r = 0.821 and r = 0.864 respec-
tively; p < 0.01). In plasma, similar mild correlations
were observed for all parameters (0.462 < r < 0.583).
TBARS versus LDH
In brain like in liver, LDH leakage was correlated positively
to TBARS in brain, liver and plasma. The most prominent
correlations were recorded between plasmatic TBARS and
brain LDH (r = 0.768; p < 0.01) and between TBARS in
brain and hepatic LDH (r = 0.768; p < 0.01). No significant
correlation was found between plasmatic LDH and
TBARS in brain, liver and plasma.
Brain TBARS versus liver TBARS
A significant but moderate positive correlation was
reported between TBARS from different compartments (r
≤ 0.528).
Brain LDH versus liver LDH
LDH leakage in the brain correlated positively with that
observed in the liver (r = 0.780; p < 0.01). The correla-
tion was weaker, yet statistically significant, between its
levels in plasma and those in brain and liver (r = 0.588
and r = 0.559 respectively; p < 0.01).
Levels of glycemia versus measured parameters
Variations of all measured parameters were correlated to
blood glucose level. The most prominent correlation
was observed for LDL-C (r = 0.909; p < 0.01), correla-
tions to total cholesterol and triglycerides were also high
(r = 0.798 and r = 0.769 respectively; p < 0.01). Lipid
peroxidation in plasma seemed more affected by glyce-
m i at h a nt h a ti nb r a i na n dl i v e r( r=0 . 7 6 4 ;r=0 . 7 0 8
and r = 0.418 respectively; p < 0.01) whereas LDH
release in these two organs was strongly correlated to
Table 2 Thiobarbituric acid-reactive substances (TBARS) and lactate dehydrogenase (LDH) activity in brain, liver and
plasma of different experimental groups.
Parameter Experimental groups
Control AlCl3 AlCl3+FSP AlCl3+FSE FSP FSE
Brain
TBARS 3.43 ± 0.35 6.12
a* ± 0.12 3.76
b* ± 0.21 2.46
b* ± 0.28 4.07 ± 0.02 4.15 ± 0.37
LDH 84.9 ± 1.27 115.8
a ± 7.21 86.4
b ± 3.65 93.3
a*b ± 0.20 83.05 ± 1.58 83.13 ± 2.64
Liver
TBARS 2.15 ± 0.18 3.11
a ± 0.24 2.75 ± 0.20 2.32
b ± 0.15 3.02
a ± 0.07 2.88
a ± 0.25
LDH 191.4 ± 6.45 282.2
a* ± 11.2 199.9
b*c* ± 0.80 185.5
b*c* ± 2.62 195.7 ± 3.49 184.9 ± 0.30
Plasma
TBARS 0.82 ± 0.03 1.21
a ± 0.09 0.79
b ± 0.02 0.91
b ± 0.02 0.88 ± 0.01 1.05a* ± 0.02
LDH 485.5 ± 14.0 1071.5
a* ± 5.59 891.5
a*b* ± 20.3 914.0
a*b* ± 0.01 575.5 ± 120.0 463.0 ± 30.8
Values are expressed as means ± SD; n = 10 for each treatment group.
a Significant difference from the control group at p < 0.05.
b Significant difference from the AlCl3-intoxicated group at p < 0.05.
c Significant difference between AlCl3+FSP and AlCl3+FSE groups at p < 0.05.
* p < 0.001.
In brain and liver TBARS and LDH are expressed respectively as: nmol MDA/mg protein and UI/g of tissue; in plasma TBARS and LDH are expressed respectively
as: nmol MDA/l and UI/l.
Table 3 Pearson correlation coefficients assessed between parameters measured in all experimental groups.
n = 60 TBARSBrain TBARSLiver TBARSPlasma LDHBrain LDHLiver LDHPlasma Glc TC TG HDL LDL
TBARSBrain 0.414* 0.528** 0.509** 0.736** 0.256 0.708** 0.556** 0.490** -0.225 0.767**
TBARSLiver 0.492** 0.480** 0.409* 0.130 0.418* 0.394* 0.280 -0.024 0.350*
TBARSPlasma 0.768** 0.613** 0.261 0.764** 0.594** 0.725** -0.247 0.640**
LDHBrain 0.780** 0.588** 0.823** 0.783** 0.795** -0.424** 0.821**
LDHLiver 0.559** 0.840** 0.782** 0.685** -0.518** 0.864**
LDHPlasma 0.511** 0.530** 0.462** -0.330* 0.583**
Glc 0.798** 0.769** -0.441** 0.909**
TC 0.657** -0.548** 0.669**
TG -0.296 0.800**
HDL -0.378*
LDL
Data are presented as r values.
* Correlation is significant at the 0.05 level (2-tailed).
** Correlation is significant at the 0.01 level (2-tailed)
Belaïd-Nouira et al. Lipids in Health and Disease 2012, 11:16
http://www.lipidworld.com/content/11/1/16
Page 3 of 8blood glucose level (r = 0.823 and r = 0.840 respectively;
p < 0.01).
Flavonoids and 4-Hydroxyisoleucine identification
To elucidate the structures of phenolic compounds mainly
flavonoids in fenugreek seeds, the aqueous methanol
extract was analyzed with diode array detection. HPLC
analysis of the fractions showed the presence of peaks
with flavonoid type UV spectra (two bands, lmax of band 1
between 320 and 350 and lmax of band 2 between 250 and
270 nm). Table 4 lists the identified compounds with their
retention time. The structure assignment of flavonoids for
which no standards were available was based on a sys-
tematic search for molecular ions using extracted ion
mass chromatograms and comparing those with data in
the literature. Thus, the ESI mass spectrum in positive
mode of compound 2 exhibited a base peak [M + H]
+at
m/z 449 and an aglycone ion at m/z 287. The loss of
162 amu from the pseudo-molecular ion indicated the
presence of a hexosyl moiety. The lmax of UV spectrum at
345 and 265 nm suggested that flavonoid 2 was a kaemp-
ferol 3-O-glucoside. Flavonoid 3 exhibited a base peak
[M + H]
+at m/z = 579 and also an intermediate ion at 433
and an aglycone ion at m/z 271. The loss of 146 amu from
pseudo-molecular ion indicated the loss of sugar rham-
nose and the loss of 162 amu from the intermediate ion
was due to the loss of glucose. The obtained MS spectra
combined to the UV spectra (lmax at 338-266) suggested
that compound 3 was apigenin 7-O-rutinoside. On the
other hand, by comparing their HPLC retention time, UV
spectra, and mass spectra with the data obtained from
standard in-house libraries, compounds 4, 5 and 6 were
identified as naringenin, quercetin and vitexin respectively.
Another amino acid compound, 4-hydroxyisoleucine (1)
was identified using an LC-MS apparatus in the positive
ionization mode. The spectrum exhibited a molecular ion
at m/z 148 [M + H]
+ with fragments at m/z 138, 130, and
118. The obtained mass fragments were consistent with
those described earlier [20].
Discussion
The major effects of aluminium-induced neurotoxicity
has been related to lipid peroxidation via free radical
production [21]. In the present experiment, there was a
significant increase in LPO after aluminium exposure in
terms of MDA levels in liver, blood and especially in
brain which confirms the susceptibility of brain to oxida-
tive insult. In brain, LPO correlated significantly with
lipid profile components in plasma principally LDL-C.
Thereby, it seems that the assayed endproducts of LPO
in posterior brain result in a great part from LDL oxida-
tion. Low-density lipoproteins are in fact highly vulner-
able to oxidative modifications especially when it is
triggered by metal ions like aluminium [22]. The strong
correlation found between LDL-C and glycemia during
this experiment suggest that hyperglycemia induced by
aluminium ingestion is the primary cause of LDL oxida-
tion. Glycated LDL is in fact a preferred target for oxida-
tive modifications [23]. A similar but stronger correlation
was found between LDL-C and LDH release in brain.
LDH leakage has been used as a marker of Al toxicity
[24]. It was found to occur simultaneously with the eleva-
tion of LPO [25] as a result of cell membrane deteriora-
tion. However, neuronal LPO is not the only cause of
cerebral damage that links LDH to LDL-C. Indeed, oxi-
dized LDL have been found to induce apoptosis of
mouse cerebrovascular endothelial cells [26] which sup-
ports the hypothesis that LPO plays a role in AD through
linking agents contributing to blood-brain barrier disrup-
tion [27]. On the other hand, unlike LPO, LDH leakage
in posterior brain appears to be highly associated to plas-
matic TC and TG levels. This might be explained in part
by the link between LDH and LDL-C given that hyperch-
olesterolemia and even hypertriglyceridemia lead to LDL-
C increase and oxidation. The LDL-C/TG ratio has yet
been suggested to be an important predictor of LDL
oxidation [28]. Nevertheless, increasing circulating cho-
lesterol could have a direct effect on LDH release as
hypercholesterolemia enhances intra-neuronal accumula-
tion and deposition in brain of b-amyloid protein [29],
which is considered to induce oxidation [30] and plays a
pivotal role in Alzheimer’s disease. Changes in the extra-
cerebral cholesterol levels could also induce modifica-
tions in brain cholesterol and low-density lipoprotein
receptors present in the blood-brain barrier [31].
Table 4 Compounds detected in fenugreek seed extract with their retention times, UV spectra and mass spectral data.
N° Flavonoid Retention time (min) UV l max (nm) [M+H]
+ (m/z)
a [I+H]
+ (m/z)
b [A+H]
+ (m/z)
c
1 4-hydroxy-isoleucine 1.6 260 148 - -
2 Kaempferol 3-O-glucoside 8.7 265, 345 449 - 287
3 Apigenin 7-O-rutinoside 12.3 338, 266 579 433 271
4 Naringenin 13 288, 330 273 - -
5 Quercetin 2 371, 255 303 - -
6 Vitexin 9.1 268, 336 433 341 -
a APCI-MS (positive mode) data for the protonated molecular ion
b APCI-MS (positive mode) data for protonated intermediate molecular ions
c APCI-MS (positive mode) data for the protonated aglycone ion
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Al administration indicates a loss of membrane integrity
[32] as it was confirmed by LDH release in brain, liver
and blood. Similarly, Al exposure can result in Al accu-
mulation in the liver leading to a disturbance of lipid
metabolism and an elevation of serum cholesterol [33].
This explains the high correlation between LDH in liver
and both LDH and TBARS in brain. This correlation is
in fact indirect because mediated by cholesterol.
Regarding the cerebral protective effect of fenugreek
seeds, we found that co-administration of fenugreek
seeds either as FSP or FSE with Al reduced significantly
levels of TBARS and LDH in brain. These results indicate
that fenugreek seeds are endowed with antiperoxidative
properties in brain which may be mediated either by
direct or indirect effects on brain. It is likely that LPO
and consequently LDH inhibition is owing to the antira-
dical and antioxidant potential of polyphenolic flavonoids
of Trigonella seeds emphasized through in vitro and in
vivo experiments [18,34-37]. Five flavonoids (kaempferol
3-O-glucoside, apigenin 7-O-rutinoside, naringenin,
quercetin and vitexin) were in fact detected in this
extract using LC-MS/MS. The well known hypoglycemic
property of fenugreek seeds has also been used to explain
its anti-peroxidative action in brain during diabetes
[17,38]. However, correlations established in this study
between LPO and LDH in brain and lipid profile suggest
that fenugreek seeds exert their neuroprotective effect via
controlling lipid and lipoprotein metabolism. Indeed, our
study showed that FSP and FSE were effective in lowering
plasma cholesterol, triglyceride and LDL-cholesterol in
AlCl3-treated rats which is in line with the previous stu-
dies [20,39,40]. Several mechanisms, in addition to var-
ious components have been suggested to explain the
lipid-lowering effect of fenugreek seeds. These include a
direct effect on cholesterol metabolism by inhibiting the
key enzymes involved in cholesterol and fatty acid synth-
esis. Number of studies has shown that steroid saponin
extracted from fenugreek seeds has the ability to modify
cholesterol status by its capacity to bind both cholesterol
and bile acids [41]. Diosgenin, a steroidal sapogenin
extracted from fenugreek seeds, has in fact been shown
to reduce TC as well as LDL-C in high-cholesterol fed
quails [42]. On the other hand, trigonelline, an alkaloid
isolated from fenugreek seeds, was found able to normal-
ize the rate of lipogenesis in streptozotocin induced
hyperglycemic rats by stimulating hepatic lipogenic
enzymes [43]. A recent study carried by Vijayakumar et
al. [44] has proven that precipitable protein/peptide or
associated factors could be responsible for improvement
in serum lipid profil through hypolipidemic effect on adi-
pocytes and liver cells leading to decreased TG and cho-
lesterol synthesis in addition to enhanced LDL receptor-
mediated LDL uptake. Nevertheless, the lipid-lowering
compounds in fenugreek seeds could be of a polypheno-
lic nature. Indeed, Wilox et al. [45] provided evidence
that naringenin not only decrease cholesterol biosynth-
esis but also inhibit acyl transferase (ACAT), a key
enzyme involved in the esterification and absorption of
cholesterol, secretion of hepatic LDL cholesterol, and
cholesterol accumulation in the arterial wall. Naringenin
is in fact a well known flavonoid which was detected in
our extract. This effect could explain the significant
increase in plasmatic HDL-C following TC decrease
when fenugreek seeds are administrated to AlCl3-treated
rats. Increasingly, hypolipidemic effect of fenugreek seeds
has been attributed to the presence of 4-hydroxyisoleu-
cine an atypical branched-chain amino acid derived from
fenugreek [46] also detected in the used FSE. However,
the action of 4-hydroxyisoleucine or galactomannan on
lipid profile, like other components of fenugreek seeds,
could be due to achievement of normoglycemia where
there was no further degradation of already accumulated
lipids for otherwise glucose starved cells [43]. Hypercho-
lesterolaemia and consequently the increase of TG and
LDL-C are in fact highly correlated to hyperglycemia. 4-
Hydroxyisoleucine was shown to display an insulinotro-
pic property in vitro, stimulate insulin secretion in vivo,
and improve glucose tolerance in normal rats and dogs
and in rat model of type 2 DM [47]. Other components
of Trigonella seeds having hypoglycemic effects include
arginine, tryptophan, ascorbic acid, niacin, nicotinic acid,
chromium, copper, magnesium, manganese, zinc, gentia-
nine, choline and quercetin, a flavonoid also detected in
our extract [48]. On the other hand, the significant hepa-
toprotective effect of fenugreek seeds as evidenced by
decreased levels of TBARS and LDH may be a secondary
indirect mechanism for its neuroprotective effect, taking
into account the high observed correlation between hepa-
tic injury induced by AlCl3 and LPO in brain. Eventually,
the decrease of LPO and LDH in brain after fenugreek
administration might also be attributed to its oestrogenic
constituents (saponines, trigoneosides, flavonoids) [49].
Their action could be direct since phytoestrogens have
shown potential neuroprotective properties [50] or indir-
ect thanks to their hypocholesterolemic effect [51].
Finally, it is worthwhile to mention that in this study,
fenugreek seeds were given either as FSP 5% or FSE (100
mg/kg) in order to make a useful comparison as for the
best form of administration. The dose of powdered fenu-
greek seeds was equated to the therapeutic dose sug-
gested for humans and has been subjected to nutritional
and safety evaluation [52] and the dose of fenugreek seed
extract was established based on a previous study which
has proved its safety and therapeutic effect [36].
Although many compounds present in the whole fenu-
greek seed could play a role in the described actions,
similarities between the effects of the whole seed (FSP) in
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other hand, suggest that a mixture of flavonoids and
4-hydroxyiseuleucine was enough to generate neuropro-
tection against Al toxicity.
Conclusion
Even if preliminary, the present study demonstrates that
aluminium-induced LPO could arise from alteration of
lipid metabolism and that is probably related to altered
lipoprotein metabolism rather than a direct effect of
cholesterol oxidation. Using fenugreek seeds either as
FSP or FSE could be neuroprotective thanks to their
antiperoxidative activity but also their ability to control
hypercholesterolemia, hypertriglyceridemia and hyper-
glycemia. Synergism among well defined components
endowed with pleiotropic actions is one of the charac-
teristics of Trigonella foenum-graecum seeds. The whole
fenugreek seed could be suggested as a regular nutrient
to protect brain from chronic aluminium toxicity. How-
ever, further investigations are imperious to adjust quan-
titatively the active compounds in the fenugreek seed
extract and provide a base for the development of nat-
ural drugs.
Materials and methods
Reagents
Aluminum chloride ((AlCl3,6 H 2O), analytical grade)
and all used chemicals were of analytical grade and were
purchased from Sigma-Aldrich Chemical Co. (St. Louis,
France).
Animals
Sixty female Wistar rats (weighing 208-220 g) were
obtained from the Central Pharmacy (SIPHAT, Tunis,
Tunisia). They were fed pellet diet, purchased from the
Industrial Society of Rodents’ Diet (SICO, Sfax, Tunisia)
and tap water ad libitum. Animals were kept in an air-
conditioned room (temperature 22 ± 3°C and relative
humidity of 40%) with a 12 h light/dark cycle. The
experimental procedures were carried out according to
the National Institute of Health Guidelines for Animal
Care and approved by the local Ethics Committee.
Plant material
Preparation of fenugreek seeds powder (FSP)
Trigonella seeds purchased from the local market were
finely powdered and mixed at 5% in ground standard
rat feed (i.e. 5 g of dry ground Trigonella seeds in 95 g
of ground rat food).
Preparation of fenugreek seeds extract (FSE)
An aqueous methanol fenugreek seeds extract was pre-
pared according to the protocol described by Kaviarasan
et al. [34]. In brief, fenugreek seeds were finely pow-
dered, mixed with 80% methanol and kept at room
temperature for 5 days. The mixture was then filtered
and the solvent was evaporated to get the residue. This
latter was dissolved in water and the aqueous layer was
washed with petroleum ether several times until a clear
upper layer of petroleum ether was obtained. The lower
layer was then treated with ethyl acetate containing gla-
cial acetic acid (10 mL/L). Extraction was then carried
o u tf o r3 6ha tr o o mt e m p e r a t u r ea n dt h ec o m b i n e d
ethyl acetate layer was concentrated. The residue was
lyophilised and stored at -20°C. The extract was dis-
solved in double-distilled water for oral administration.
Characterization of fenugreek seed extract by LC-MS/MS
analysis
The LC-MS/MS experiments were performed as
described previously by Belghith-Hadrich et al. [20] using
an Agilent 1100 LC system consisting of a degasser, a
binary pump, an autosampler and a column heater. The
column outlet was coupled with an Agilent MSD Ion
Trap XCT mass spectrometer equipped with an ESI ion
source. Data acquisition and mass spectrometric evalua-
tion were carried out in a personal computer with Data
Analysis software (Chemstations). For the chromato-
graphic separation, a Zorbax 300 Å Extend-C-18 Column
(2.1 × 150 mm) was used. The flavonoids and other com-
pounds were identified using a combination of HPLC
with diode array detection and liquid chromatography
coupled with an electrospry ionization mass spectrometry
(ESI-LC-MS/MS) on the basis of their UV spectra and
mass spectra and by comparison of the spectra with
those of available authentic standards.
Study design
Rats were treated according to the protocol established
by Gong et al. [53] in which a brain dysfunction model
was established. In brief, rats, randomly distributed into
six groups of ten animals each, were given a daily AlCl3
solution (500 mg/kg, i.g, 0.5 mL/100 g) or saline
(0.5 mL/100 g, i.g. for control) for the first month, and
then fed with an AlCl3 solution (1600 ppm in drinking
water) for up to 5 months. Three months after Al
administration, rats were given either FSP 5% in pow-
dered rat feed or FSE (100 mg/kg, i.g) for two months
together with AlCl3.
Blood and tissue collection
Blood samples were collected under anesthesia by cardiac
puncture in heparinized tubes. Plasma was separated
from the blood cells by centrifuging the blood at 3,000xg
for 15 min at 4°C and stored in aliquots at -20°C until
analysis. Livers and brains were removed quickly from
animals, washed in ice-cold physiological saline. Then,
multiple lobes of the liver from each rat were cut out,
minced and homogenized (10% w/v) separately in ice-
cold 1.15% KCl-0.01 mol/L sodium, potassium phosphate
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Page 6 of 8buffer (pH 7.4) in a Potter-Elvehjem type homogenizer.
The homogenate was centrifuged at 10,000x g for 20 min
at 4°C, and the resultant supernatant was stored at -80°C
to be used for different enzyme assays.
Regarding the brain, temporal and parietal lobes were
isolated from one hemisphere of each brain by free
hand dissection on ice according to the method of Glo-
wenski and Iversen [54]. Brain tissue was minced and
homogenized (10% w/v) in ice-cold 0.1 M phosphate
buffer (pH 7.4) then centrifuged at 10,000x g for 30 min
at 4°C, the resultant supernatant was used for different
enzyme assays.
Biochemical assays
Determination of blood lipids and glucose levels
Plasmatic cholesterol, triglycerides, glucose, total protein
content and HDL-C levels were quantified by enzymatic
methods using commercial kits (Randox-Antrim, UK).
Plasmatic LDL-C level was calculated according to the
Friedewald equation [55].
Lipid Peroxidation Estimation
The extent of lipid peroxidation was assessed by mea-
suring the content of thiobarbituric acid reactive sub-
stances (TBARS) following the method of Yoshioka et
al. [56] in plasma and the method of Buege and Aust
[57] in liver and brain. TBARS were expressed as mal-
ondialdehyde (MDA) amount using freshly diluted mal-
ondialdehyde bisdimethylacetal as standard.
Lactate dehydrogenase activity
The activity of LDH in plasma, liver and brain was mea-
sured using commercial reagent kits (Randox-Antrim,
UK).
Statistical Analysis
Data were expressed as mean ± standard deviation (SD)
and analyzed using one-way analysis of variance
(ANOVA) followed by the post hoc Tukey’s test, used
for comparison. Bivariate correlation between variables
using Pearson’s correlation coefficient r value was used.
Values were considered statistically significant when p <
0.05. Statistics were done using IBM SPSS Statistics 19.
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